October 06, 2020
3 min watch
Save
VIDEO: Don’t leave PKI analysis behind in lung cancer immunotherapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, James Stevenson, MD, a medical oncologist and hematologist at Cleveland Clinic, highlighted findings from the PIONeeR trial, which was presented at ESMO Virtual Congress 2020.
“Pharmacokinetics is worthy of a bit more study in immunotherapies because ...some of [us] think that pharmacokinetics might not matter as much as they do with chemo-therapeutics,” Stevenson said. “But it may turn out that PKI analyses are important for immunotherapies as well.”
References:
- Barlesi F, et al. Abstract LBA53. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Stevenson reports receiving clinical trial research funding from Bristol-Meyers Squibb and Merck.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.